BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
|
|
- Valentine Fletcher
- 5 years ago
- Views:
Transcription
1 BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review Date: December 2017 Bulletin 206 : DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendations DuoResp Spiromax is recommended for use in adults with asthma and COPD as an alternative to first line Symbicort Turbohaler in new and existing patients. Medicine DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol breath-actuated dry powder inhaler. Doses are therapeutically equivalent to Symbicort Turbohaler (budesonide and formoterol) Product Delivered dose (microgram) Metered dose (microgram) Document status Page 1 of 11 DuoResp Spiromax Symbicort Turbohaler DuoResp Spiromax Symbicort Turbohaler Final 160/ /6 160/ /6 320/9 400/12 320/9 400/12
2 Date of last revision November 2014 Proposed Sector of Primary care / secondary care prescribing Introduction Summary Key points Evidence level The intervention Mechanism of action DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler is a breath-actuated dry powder inhaler presentation containing the inhaled corticosteroid (ICS), budesonide and the long acting bronchodilator agent (LABA) formoterol. They contain the same active ingredients, and doses have been shown to be therapeutically equivalent to Symbicort (budesonide and formoterol) Turbohaler 200/6 and 400/12. Symbicort Turbohaler is included in the CCG medicine formularies and the Bedfordshire and Luton COPD guidelines. DuoResp Spiromax is less costly than Symbicort Turbohaler and so using this device as a first line option instead of Symbicort Turbohaler would produce financial savings. From October 2013 to September 2014, 895,438 was spent on Symbicort Turbohaler 400/12 and 200/6 strengths within Bedfordshire CCG. If the equivalent doses of DuoResp Spiromax had been used in place of Symbicort Turbohaler, this would have saved 189,220 within Bedfordshire CCG. There is also the potential to disinvest in other more costly ICS/LABA combination dry powder inhalers used in asthma and/or COPD. Inhaled corticosteroid (ICS) and long acting beta2-agonist (LABA) combination inhaler. Licensed indication DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler is indicated in adults 18 years of age and older only (1) Asthma DuoResp Spiromax is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: -in patients not adequately controlled with inhaled corticosteroids and as needed inhaled short-acting β2 adrenoceptor agonists. or -in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. COPD Symptomatic treatment of patients with severe COPD (FEV1 < 50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular therapy with long-acting bronchodilators. Page 2 of 11
3 Formulation/Available Products Usual dosage Treatment alternatives/ place in therapy Breath-actuated dry powder inhaler of inhaled corticosteroid and long-acting beta-agonist. Spiromax is a breath actuated, inspiratory flow-driven inhaler, which means that the active substances are delivered into the airways when the patient inhales through the mouthpiece. DuoResp Spiromax 160 microgram / 4.5 microgram dry powder inhaler. Each delivered dose (the dose that leaves the mouthpiece of the Spiromax) contains 160 of budesonide and 4.5 of formoterol fumarate dihydrate. This is equivalent to a metered dose of 200 budesonide and 6 of formoterol fumarate dihydrate. DuoResp Spiromax 320 microgram / 9 microgram dry powder inhaler. Each delivered dose (the dose that leaves the mouthpiece of the Spiromax) contains 320 of budesonide and 9 of formoterol fumarate dihydrate. This is equivalent to a metered dose of 400 budesonide and 12 of formoterol fumarate dihydrate. A randomised, open-label placebo study was performed in children and adolescents with asthma (aged 6-17 years), adults with asthma (aged years), adults with chronic obstructive pulmonary disease (COPD aged >50 years) and healthy volunteers (aged years) to evaluate the peak inspiratory flow rate (PIFR) and other related inhalation parameters following inhalation from a Spiromax device (containing placebo) compared with inhalation from an already marketed multi-dose dry powder inhaler device (containing placebo). The impact of enhanced training in dry powder inhaler inhalation technique on inhalation speed and volume was also assessed in these subject groups. The data from the study indicated that regardless of age and underlying disease severity, children, adolescents and adults with asthma as well as patients with COPD were able to able to achieve inspiratory flow rates through the Spiromax device that were similar to those generated through the marketed multi-dose dry powder inhaler device. The mean PIFR achieved by patients with asthma or COPD was over 60L/min, a flow rate at which both devices studied are known to deliver comparable amounts of drug to the lungs. Very few patients had PIFRs below 40L/min; when PIFRs were less than 40L/min there appeared to be no clustering by age or disease severity. 1 or 2 inhalations twice. The BCCG current formulary choice ICS/LABA combination inhalers are (2): Asthma Fostair cfc free inhaler 100microgram/6microgram Page 3 of 11
4 Symbicort 100/6 Turbohaler Symbicort 200/6 Turbohaler COPD Fostair cfc free inhaler 100microgram/6microgram Symbicort 400/12 Turbohaler ICS/LABA combination inhalers are recommended in steps 3 and 4 of the BTS/SIGN asthma guidelines (3). For adults and children aged 12 years and older with chronic asthma in whom treatment with an ICS and long-acting beta-2 agonist (LABA) is considered appropriate, the following apply: The use of a combination device within its marketing authorisation is recommended as an option. The decision to use a combination device or the two agents in separate devices should be made on an individual basis, taking into consideration therapeutic need and the likelihood of treatment adherence. If a combination device is chosen then the least costly device that is suitable for the individual is recommended. The Bedfordshire and Luton COPD guidelines recommend an ICS / LABA combination inhaler within the primary care pathway in patients with a FEV1 <50% when a maintenance bronchodilator is required when a short acting bronchodilator (SABA) alone does not control symptoms, and treatment with a LAMA inhaler has been ineffective after 4 weeks (4). Future alternatives Fostair NEXThaler -100 / 6 beclometasone / formoterol dry powder inhaler Page 4 of 11
5 National guidance BTS/ SIGN asthma guideline- ICS/LABA combination inhalers are recommended in steps 3 and 4 of the guidelines. No specific product is recommended, but it is suggested to prescribe the product with the lowest acquisition cost (3). DuoResp Spiromax is not included in the NICE technology appraisal programme or the topic of a evidence summaries: new medicines. Scottish Medicines Consortium (SMC) will not be reviewing as DuoResp Spiromax fits within criteria no. 13 of the Medicines Outwith SMC remit, The Marketing Authorisation is solely for a new presentation or strength of an existing proprietary medicine, with no associated change to the licensed indication and the new product costs the same or less. This includes new devices for the administration/delivery of established medicines. (6) All Wales Medicines Strategy Group (AWMSG) does not appraise products which represent a new formulation of an established medicine which is costs the same or less than the existing medicine. (7) Local Guidance JPC bulletin 176. Choice of Inhaled Corticosteroid / Long Acting Beta2 Agonist (ICS/LABA) combination therapy for the treatment of asthma in adult patients, updated Sept (8) JPC Recommendation: To recommend the use of Fostair (beclometasone in combination with formoterol) (+/- a spacer device) for asthma in new patients who fulfil the licensing requirements (including use in a maintenance and reliever treatment regimen ) and NICE TAG 138 criteria. Patients on existing combination inhalers may be switched to Fostair if clinically appropriate, but care must be taken to avoid dose conversion errors as the beclometasone (BDP) in Fostair is present as extra fine particles. 100 of beclometasone extra-fine is equivalent to 250 of beclometasone non extra-fine and so dose conversions are required if switching from another CFC free BDP inhaler. Symbicort Turbohaler (budesonide in combination with formoterol) is an appropriate second line choice if a dry powder inhaler is the preferred device when an MDI plus a spacer is not suitable for the patients. Salmeterol containing combination products may be prescribed for patients who are intolerant of formoterol. The Committee agreed that a high dose steroid combination product should not be included in the recommendations as use of such products should be considered on an individual patient Page 5 of 11
6 basis and step down of treatment should be done wherever appropriate. The BCCG current formulary choice ICS/LABA combination inhalers are (2): Asthma Fostair cfc free inhaler 100microgram/6microgram Symbicort 100/6 Turbohaler Symbicort 200/6 Turbohaler COPD Fostair cfc free inhaler 100microgram/6microgram Symbicort 400/12 Turbohaler Evidence for use Safety * Bedfordshire and Luton COPD guidelines, Updated 2013.(4) Bedfordshire and Luton COPD guidelines recommend an ICS / LABA combination inhaler within the primary care pathway in patients with a FEV1 <50% when a maintenance bronchodilator is required when a short acting bronchodilator (SABA) alone does not control symptoms, and treatment with a LAMA inhaler has been ineffective after 4 weeks. First choice ICS/LABA combination inhalers are Fostair MDI and Symbicort Turbohaler. Second choice ICS/LABA combination inhaler is Seretide 500 Accuhaler. The European Medicines Agency CHMP assessment report of DuoResp Spiromax concluded that the presence of clinical efficacy studies comparing the test and reference products in adults or adolescents is not required since the clinical efficacy of budesonide and formoterol fumarate dihydrate has been investigated extensively, is well known and has been the subject of many publications. Moreover, this is in line with the CHMP Guideline on orally inhaled products (CHMP/EWP/4151/00 Rev. 1) since equivalence has been demonstrated for the high strength (320/9 microgram per dose) and the middle strength (160/4.5 microgram per dose). The two pivotal pharmacokinetic studies in the high strength (320/9 microgram per dose) and the middle strength (160/4.5 microgram per dose) demonstrated equivalence between budesonide / formoterol Spiromax and Symbicort Turbohaler for all comparisons both with and without a charcoal blockade. (9) Since DuoResp Spiromax contains budesonide and formoterol, the same pattern of adverse reactions as reported for these substances may occur. No increased incidence of adverse reactions has been seen following concurrent administration of the two compounds (1). Refer to the Summary of Product Characteristics for a full list of current potential adverse reactions available at: Page 6 of 11
7 Costs (Chemist & Druggist October 2014) Tariff status Activity costs Cost effectiveness (if available) Cost comparison for low dose ICS/LABA combination inhaler ( beclometasone) Drug Adult Dosage Beclometason e equivalent dose Fostair NEXThaler 100/6 Fostair MDI 100/6 DuoResp Spiromax DPI 160/4.5 Seretide 50 Evohaler Seretide 100 Accuhaler Flutiform 50/5 MDI Symbicort Turbohaler 200/6 2 puffs twice 2 puffs twice day cost Annual Cost per patient Cost comparison for medium dose ICS/LABA combination inhaler (> beclometasone) Drug Adult Dosage Beclometason e equivalent dose 30 day cost Annual Cost per patient Relvar Ellipta 1 puff /22 Flutiform 2 puffs twice /5 MDI Fostair 2 puffs twice NEXThaler Fostair MDI 2 puffs twice DuoResp Spiromax DPI 160/4.5 Seretide 125 Evohaler Seretide 250 Accuhaler Symbicort Turbohaler 200/6 Symbicort Turbohaler 2 puffs twice 2 puffs twice 2 puffs twice /12 N.B. Doses are for general comparison and do not imply therapeutic equivalence Potential number of patients in DuoResp Spiromax is less costly than Symbicort Turbohaler and so using this device as an alternative to Symbicort Page 7 of 11
8 Bedfordshire and Luton Impact per 100,000 population Affordability considerations Decisions from other bodies Comments sought from Turbohaler would produce financial savings. From October 2013 to September 2014, 895,438 was spent on Symbicort Turbohaler 400/12 and 200/6 strengths within Bedfordshire CCG. If the equivalent doses of DuoResp Spiromax had been used in place of Symbicort Turbohaler, this would have saved 189,220 within Bedfordshire CCG. There is also the potential to disinvest in other more costly ICS/LABA combination dry powder inhalers used in asthma and/or COPD. Respiratory Consultants Bedford Hospital and L&D Hospital Respiratory Nurses Bedford Hospital and L&D Hospital BCCG and LCCG GP Respiratory Leads Points for Doses of DuoResp Spiromax are therapeutically equivalent to consideration Symbicort Turbohaler in terms of efficacy and tolerability and the products have been shown to have a similar safety profile. Some patients may find DuoResp Spiromax easier to use than Symbicort Turbohaler. DuoResp Spiromax is less costly than Symbicort Turbohaler. PAC New Drug Template Adapted from East Anglia Medicines Information, NHS Suffolk, NHS Cambridgeshire and NHS Derby templates *Consult Summary of Prescribing Characteristics for full prescribing detail. This guidance is based upon the published information available in English at the time the drug was considered. It remains open to review in the event of significant new evidence emerging. References / Sources of Review 1) SPC DuoResp Spiromax 160 microgram / 4.5 microgram and 320 microgram / 9 microgram inhalation powder. Teva Pharma B.V. Last updated 22/9/14 and accessed 11/11/14. Available at 2) BCCG Primary Care Medicines Formulary last updated September 2014 and available at: 3) British Guidelines on the management of asthma October SIGN 141. British Thoracic Society / Scottish Intercollegiate Guidelines Network. Available at 4) Bedfordshire and Luton COPD Guidelines Updated Available at: 5) SPC DuoResp Spiromax Teva UK Limited. Last updated 22/9/14 and accessed 16/10/14. Available at 6) Scottish Medicines Consortium (SMC). Guidance to Manufacturers on Medicines outwith SMC Remit. Available at: 7) All Wales Medicines Strategy Group (AWMSG). Appraisal exclusion criterion number 6. Available at: 8) Bedfordshire and Luton Joint Prescribing Committee, Bulletin 176 Choice of inhaled corticosteroid / long acting beta2 agonist (ICS/LABA) combination therapy for the treatment of asthma in adult patients, updated September Available at: UpdatedSept13.pdf 9) The European Medicines Agency. CHP Assessment Report. DuoResp Spiromax. Procedure No. EMEA/H/C/ February Available at: _Public_assessment_report/human/002348/WC pdf N:\Medicines Management\JPC\Approved Bulletins and Papers\from Aug 13 )\Dec 14 Page 8 of 11
9 Bedfordshire and Luton Joint Prescribing Committee (JPC) Assessment against Ethical and Commissioning Principles Treatment assessed (December 2014): DuoResp Spiromax 160 / 4.5 and 320 / 9 budesonide & formoterol dry powder inhaler JPC Recommendation: DuoResp Spiromax is recommended for use in adults with asthma and COPD as an alternative to first line Symbicort Turbohaler in new and existing patients. 1) Clinical Effectiveness The European Medicines Agency CHMP assessment report of DuoResp Spiromax concluded that the presence of clinical efficacy studies comparing the test and reference products in adults or adolescents is not required since the clinical efficacy of budesonide and formoterol fumarate dihydrate has been investigated extensively, is well known and has been the subject of many publications. Moreover, this is in line with the CHMP Guideline on orally inhaled products (CHMP/EWP/4151/00 Rev. 1) since equivalence has been demonstrated for the high strength (320/9 microgram per dose) and the middle strength (160/4.5 microgram per dose). The two pivotal pharmacokinetic studies in the high strength (320/9 microgram per dose) and the middle strength (160/4.5 microgram per dose) demonstrated equivalence between budesonide / formoterol Spiromax and Symbicort Turbohaler for all comparisons both with and without a charcoal blockade. (9) 2) Cost Effectiveness DuoResp Spiromax is less costly than Symbicort Turbohaler and so using this device as an alternative to Symbicort Turbohaler would produce financial savings. From October 2013 to September 2014, 895,438 was spent on Symbicort Turbohaler 400/12 and 200/6 strengths within Bedfordshire CCG. If the equivalent doses of DuoResp Spiromax had been used in place of Symbicort Turbohaler, this would have saved 189,220 within Bedfordshire CCG. There is also the potential to disinvest in other more costly ICS/LABA combination dry powder inhalers used in asthma and/or COPD. 3) Equity No issues identified. 4) Needs of the community Asthma prevalence (both GP treated and symptoms untreated) is estimated to be 16% in women and 13% in men (Health Survey England, 2001). QoF 2012 prevalence across England showed that prevalence of GP treated asthma was estimated at 5.9% on average. In Bedfordshire the prevalence is slightly higher than national average at 6.4% (27,877 patients approximately) and in Luton it is slightly lower at 5.4% (11,562 patients approximately) (data from NHS information Centre Disease prevalence QoF for ) Page 9 of 11
10 Prescribing rates suggest that a large proportion of asthma patients are being over treated on High dose inhaled corticosteroids and there is a need to address this. COPD prevalence is estimated at 2-4% but the diagnosed prevalence is about 1.5% (1,500 per 100,000) which increases to 10% in men aged over An average GP practice of 6,600 patients is likely to have about 100 patients on its COPD disease register. This equates to approximately 6,100 and 3,000 patients with COPD in Bedfordshire and Luton respectively. 5) Need for healthcare (incorporates patient choice and exceptional need) There are a number of ICS/LABA combination inhalers available to treat asthma and COPD including Symbicort Turbohaler and Fostair 100/6 MDI. 6) Policy drivers ICS/LABA combination inhalers are recommended in steps 3 and 4 of the BTS/SIGN asthma guidelines (3). For adults and children aged 12 years and older with chronic asthma in whom treatment with an ICS and long-acting beta-2 agonist (LABA) is considered appropriate, the following apply: The use of a combination device within its marketing authorisation is recommended as an option. The decision to use a combination device or the two agents in separate devices should be made on an individual basis, taking into consideration therapeutic need and the likelihood of treatment adherence. If a combination device is chosen then the least costly device that is suitable for the individual is recommended. The Bedfordshire and Luton COPD guidelines recommend an ICS / LABA combination inhaler within the primary care pathway in patients with a FEV1 <50% when a maintenance bronchodilator is required when a short acting bronchodilator (SABA) alone does not control symptoms, and treatment with a LAMA inhaler has been ineffective after 4 weeks (4). 7) Disinvestment There is the potential to disinvestment in more costly ICS/LABA combination dry powder inhalers. The JPC agreed the following sections within the PCT Ethical and Commissioning Framework were not relevant to JPC discussions: Health Outcomes, Access, and Affordability. Page 10 of 11
11
Include patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationStepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs
Step Down guidance Stepping-down combination ICS/LABA asthma inhaler therapy: Adults 18yrs Important Complete asthma control needs to be achieved for at least 12 weeks before attempting to step patients
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationAdult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred inhaler choices
ENHCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to ENHCCG preferred
More informationAdult Summary flowchart for Asthma Switch and Step Down to preferred inhaler choices
HVCCG Adult Asthma Switch and Step Down Algorithms - Approved by Hertfordshire Medicines Management Committee June 2016 Page 1 of 6 Adult Summary flowchart for Asthma Switch and Step Down to preferred
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationfluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK
fluticasone furoate / vilanterol 92/22, 184/22 micrograms inhalation powder (Relvar Ellipta ) SMC No. (966/14) GlaxoSmithKline UK 09 May 2014 The Scottish Medicines Consortium (SMC) has completed its assessment
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationASTHMA TREATMENT GUIDE (ADULTS)
ASTHMA TREATMENT GUIDE (ADULTS) The BTS/SIGN guideline provides a wide range of information and guidance on the treatment of patients with asthma. https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationStepping down asthma treatment guidelines
Stepping down asthma treatment guidelines The potential for inhaled corticosteroids (ICS) to cause dose-related side-effects has led to asthma management guidelines recommending a dose reduction once asthma
More informationMedicines Optimisation Team Standard Operating Procedure for Audit: High Dose Inhaled Corticosteroids
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) February 2013, Updated September 2013 Review date: September 2016 Bulletin 176 : Choice of Inhaled Corticosteroid / Long Acting Beta 2 Agonist (ICS/LABA)
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE September 2015 Review Date: September 2018 Bulletin 219: Choice of Long Acting Muscarinic Agent (LAMA) inhaler for COPD JPC Recommendation: The availability
More informationInhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years & over
Manufacturer Submission To The National Institute for Health and Clinical Excellence By GlaxoSmithKline UK Inhaled Corticosteroids for the Treatment of Chronic Asthma in Adults & Adolescents aged 12 years
More informationAWMSG SECRETARIAT ASSESSMENT REPORT
AWMSG SECRETARIAT ASSESSMENT REPORT Fluticasone furoate/vilanterol (as trifenatate) (Relvar Ellipta ) inhalation powder, 184/22 inhalation powder Reference number: 1216 FULL SUBMISSION This report has
More informationIvax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence
Ivax Pharmaceuticals UK Sponsor Submission to the National Institute for Health and Clinical Excellence Clinical and cost-effectiveness of QVAR for the treatment of chronic asthma in adults and children
More informationSeretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD.
Seretide 250mcg/125mcg Evohaler switch to Fostair 100/6 MDI in COPD. Applies to HaRD CCG employed Pharmacists and Medicines Optimisation Technicians These protocols are produced by the NY&AWC MM team hosted
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationGMMMG Asthma Formulary Inhaler Options August 2017
Regular Preventer Beclometasone Beclometasone Beclometasone Brand name Qvar Easi-Breathe Clenil Modulite Easyhaler Device MDI MDI DPI Strengths 50 microgram 100 microgram 200 microgram Adult asthma 2 inhalations
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE December 2014 Review date: December 2017 Bulletin 208 : Indacaterol + Glycopyrronium bromide 85/43 micrograms (Ultibro Breezhaler ) for the Treatment
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationBeclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults
CLENIL MODULITE Beclometasone dipropionate (BDP) Prophylactic management of mild, moderate or severe asthma in adults Corticosteroids for the treatment of chronic asthma in adults and children aged 12
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationScottish Medicines Consortium
Scottish Medicines Consortium budesonide/formoterol 100/6, 200/6 turbohaler (Symbicort SMART ) No. (362/07) Astra Zeneca UK Limited 9 March 2007 (Issued May 2007) The Scottish Medicines Consortium (SMC)
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationTechnology appraisal guidance Published: 28 November 2007 nice.org.uk/guidance/ta131
Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years Technology appraisal guidance Published: 28 November 2007 nice.org.uk/guidance/ta131 NICE 2018. All rights
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationInhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years. Issue date: November 2007
Issue date: November 2007 Review date: November 2012 Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years NICE technology appraisal guidance 131 NICE technology
More informationProgress, Paediatrics and Protocols. Dr Andy Powell Dr Lesley Ayling West Hampshire CCG
Progress, Paediatrics and Protocols Dr Andy Powell Dr Lesley Ayling West Hampshire CCG Progress Solutions CQUIN discharge bundle (including personal action plan), specialist review, immediate management
More informationNew Medicine Review. Racecadotril for the symptomatic treatment of acute diarrhoea (adults and children over 3 months)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) April 2013 Review date: April 2016 Bulletin 180: Racecadotril for the symptomatic treatment of acute diarrhoea in adults and children over 3 months
More informationBulletin Independent prescribing information for NHS Wales
Bulletin Independent prescribing information for NHS Wales Respiratory disease September 2014 Respiratory diseases account for one in seven of all deaths in Wales the third largest cause of mortality for
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationAnnex I. Scientific conclusions and grounds for refusal presented by the European Medicines Agency
Annex I Scientific conclusions and grounds for refusal presented by the European Medicines Agency Scientific conclusions and grounds for refusal presented by the European Medicines Agency Overall summary
More informationError! No text of specified style in document.
Inhaled corticosteroids and long-acting beta 2 -agonists for the treatment of chronic asthma in children under the age of 12 years: Systematic review and economic analysis Amended cost-off set comparisons
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationStudy designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views
IPAC-RS/University of Florida Study designs and PD/Clinical endpoints to demonstrate therapeutic equivalence: European Views 20 th March 2014 Dr. Alfredo García - Arieta Head of the Service of Generic
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationrequesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group
requesting information regarding prescribing incentive schemes in Canterbury and Coastal Clinical Commissioning Group Canterbury and Coastal Clinical Consortium Group Medicine Management plans 2013/14
More informationMedicines Management of Asthma
Wandsworth Borough Team Medicines Management of Guidelines for Primary Care September 2011 Version 1 Guideline Authors: Shaneez Dhanji (Wandsworth borough) Reena Rabheru-Dodhy (Sutton & Merton borough)
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC)
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE (JPC) June 2017 Review: June 2020 (earlier if required see recommendations) Bulletin 255: Insulin aspart New Formulation - Fiasp JPC Recommendations:
More informationDiagnosis and management of Asthma in Adults. (Version 1.1)
Pan-Birmingham Respiratory Clinical Network Diagnosis and management of Asthma in Adults (Version 1.1) Revision History Guideline Author: Guideline Sponsor: Date of Approval: 23/03/2017 Approved by: Date
More informationNOVOLIZER BUDESONIDE. Corticosteroids for the treatment of chronic asthma in children under the age of 12 years
NOVOLIZER BUDESONIDE Corticosteroids for the treatment of chronic asthma in children under the age of 12 years Response to the assessment report produced by the Peninsula Technology Assessment group and
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationScottish Medicines Consortium
Scottish Medicines Consortium montelukast 10mg tablets (Singulair ) No. (185/05) Merck, Sharp & Dohme Ltd (MSD) New indication: for asthmatic patients in whom montelukast is indicated in asthma, montelukast
More informationRESPIRATORY CARE IN GENERAL PRACTICE
RESPIRATORY CARE IN GENERAL PRACTICE Definitions of Asthma and COPD Asthma is due to inflammation of the air passages in the lungs and affects the sensitivity of the nerve endings in the airways so they
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationroflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd
roflumilast 500 microgram tablets (Daxas ) SMC No. (635/10) Nycomed Ltd 06 August 2010 (Issued 10 September 2010) The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationPutting NICE guidance into practice. Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80)
Putting NICE guidance into practice Resource impact report: Asthma: diagnosis, monitoring and chronic asthma management (NG80) Published: November 2017 Summary This report focuses on the recommendations
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationPocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals
Pocket Guide to Inhaler Technique A Step-By-Step Guide for Healthcare Professionals Endorsed by NHSGGC Respiratory Managed Clinical Network; June 2016 Designed by Medical Illustration Services Contents
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1833/5/06 ASTRAZENECA v GLAXOSMITHKLINE CONCEPT study leavepiece AstraZeneca complained that a leavepiece issued by Allen & Hanburys, part of GlaxoSmithKline, did not present a fair and balanced
More informationbeclometasone 100 MDI 2 puffs twice a day (recently changed to non CFC (Clenil Modulite))
Case 1 Mr Thomson, a 32 year old asthmatic who is well known to you comes into your pharmacy. He is known to have a best peak flow of 640 L/min. He tells you that over the last few weeks he has been wakening
More informationPublic Assessment Report Scientific discussion. Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC
Public Assessment Report Scientific discussion Salmeterol/Fluticasone Sandoz (salmeterol xinafoate, fluticasone propionate) SE/H/1323/03/DC This module reflects the scientific discussion for the approval
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationLong-acting bronchodilators: their properties and place in treatment
Long-acting bronchodilators: their properties and place in treatment Steve Chaplin MSc, MRPharmS and Paul Walker BMedSci (Hons), MD, FRCP Steve Chaplin and Dr Paul KEY POINTS Walker provide an overview
More informationInformation for Parents and Young People on New and Emerging Treatments in Asthma
Information for Parents and Young People on New and Emerging Treatments in Asthma Asthma continues to be a very common condition that causes a lot of distress to children and their families. For some it
More informationYear in review. Vit Perlik Director of Regulatory Science and Clinical Development
Year in review Vit Perlik Director of Regulatory Science and Clinical Development Content Year in review Covering September 2013 to September 2014 Where the regulation goes selection of events for illustration
More informationumeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline
umeclidinium/vilanterol, 55/22 micrograms, inhalation powder (Anoro ) SMC No. (978/14) GlaxoSmithKline 04 July 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNew Medicines Committee Briefing March 2013
New Medicines Committee Briefing March 2013 Fluticasone proprionate/formoterol fumerate inhaler (Flutiform ) for the treatment of patients with asthma. Flutiform is to be reviewed for use within: Summary
More informationNHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group
NHS Northern, Eastern and Western Devon Clinical Commissioning Group NHS South Devon and Torbay Clinical Commissioning Group Inhaler technique and respiratory conditions Guidance Sheet 16 When diagnosed
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationRelvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD
Relvar Ellipta (fluticasone furoate and vilanterol as trifenatate) for the treatment of patients with COPD Medicines evidence pack to support formulary and guidelines decision making Prescribing information
More informationIf you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division:
More informationAWMSG SECRETARIAT ASSESSMENT REPORT. Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder. Reference number: 938 FULL SUBMISSION
AWMSG SECRETARIAT ASSESSMENT REPORT Aclidinium bromide (Eklira Genuair ) 322 micrograms inhalation powder Reference number: 938 FULL SUBMISSION This report has been prepared by the All Wales Therapeutics
More informationAsthma Guidelines and Pharmacological Treatment. Dr James Wilkinson
Asthma Guidelines and Pharmacological Treatment Dr James Wilkinson Asthma is a common disease in the UK 5.4 million people in the UK are currently receiving treatment for asthma: 4.3 million adults (1
More informationA multitude of devices
A multitude of devices Dr Andrew Scroop Respiratory Consultants 15 th September 2018 STEPWISE PHARMACOLOGICAL MANAGEMENT OF STABLE COPD COPD Inhalers MILD FEV 1 60 80% predicted few symptoms breathless
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationRespiratory Health. Asthma and COPD
Respiratory Health Asthma and COPD Definition of asthma Working definition by AAH 2014: Chronic lung disease Can be controlled not cured Large variation in lung function Large variation in respiratory
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationDate of Preperation: September 2014 IE/DUOSP/14/0010. Product monograph
Date of Preperation: September 2014 IE/DUOSP/14/0010 Product monograph Contents Introduction Part I: Scientific Information 1. Disease background 1.1 Avallable treatments 1.2 GINA guidelines: stepwise
More informationSuffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice)
Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and further notice) This drug has been reviewed because it is a product that may be prescribed in primary
More informationResponsible Respiratory Prescribing
Responsible Respiratory Prescribing Dr Vincent Mak Consultant Physician in Respiratory Integrated Care Imperial College Healthcare and Central London Community Healthcare NHS Trust Respiratory Clinical
More information